Attana features in Pharma Publications with AVA™ as a leading-edge solution for improved SARS-CoV-2 testing and immunity profiling
Recently, an article about Attana’s first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics – AVA™, was published in IBI (International Biopharmaceutical Industry). The article explains how AVA could help provide invaluable insights when assessing patient immunity for SARS-CoV-2.A brief summary of the article: The Challenge of Assessing SARS-CoV-2 ImmunityOne of the main challenges with SARS-CoV-2 is assessing patient immunity. Conventional testing methods focuse on the binary presence of virus-specific antibodies (e.g. IgA, IgM and IgG). However, SARS-CoV-2